TY - JOUR
T1 - Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders
AU - Warden, Diane
AU - Sanchez, Katherine
AU - Greer, Tracy
AU - Carmody, Thomas
AU - Walker, Robrina
AU - dela Cruz, Adriane
AU - Toups, Marisa
AU - Rethorst, Chad
AU - Trivedi, Madhukar H.
N1 - Publisher Copyright:
© 2016 Elsevier Ireland Ltd
PY - 2016/12/30
Y1 - 2016/12/30
N2 - This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6%, and anxiety disorders in 29.6%, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.
AB - This study aimed to determine if current comorbid psychiatric disorders differ in adults with cocaine use disorder, other stimulant (primarily methamphetamine) use disorder, or both, and identify demographic and clinical characteristics in those with increasing numbers of comorbid disorders. Baseline data from a randomized controlled trial beginning in residential settings (N=302) was used. Mood disorders were present in 33.6%, and anxiety disorders in 29.6%, with no differences among stimulant use disorder groups. Panic disorder was more frequently present with other stimulant use disorder. Those with two or more comorbid psychiatric disorders were more often female, White, had more symptoms of depression, greater propensity and risk for suicidal behavior, lower functioning in psychiatric and family domains, lower quality of life, more symptoms with stimulant abstinence and greater likelihood of marijuana dependence. Those with one or more comorbid disorders had more medical disorder burden, lower cognitive and physical functioning, greater pain, and higher rates of other drug dependence. With current comorbid psychiatric disorders, the morbidity of stimulant use disorders increases. Use of validated assessments near treatment entry, and a treatment plan targeting not only substance use and comorbid psychiatric disorders, but functional impairments, medical disorder burden and pain, may be useful.
KW - Cocaine
KW - Comorbidities
KW - Methamphetamine
KW - Panic disorder
KW - Residential treatment
KW - Substance use disorder
UR - http://www.scopus.com/inward/record.url?scp=84988933736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988933736&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2016.09.007
DO - 10.1016/j.psychres.2016.09.007
M3 - Article
C2 - 27693866
AN - SCOPUS:84988933736
SN - 0165-1781
VL - 246
SP - 136
EP - 141
JO - Psychiatry research
JF - Psychiatry research
ER -